Showing results (801-810 of 863) with videos related to
Sort By:
Pageof 87
Journal of Pediatric and Adolescent Gynecology|October 7, 2024
Bladder Health Knowledge, Attitudes, and Beliefs among US Adolescent WomenDeepa R Camenga, Sonya S Brady, Andrea Bilger, et al.British Journal of Haematology|June 10, 2000
A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular responseJ M Foran, R K Gupta, D Cunningham, et al.European Journal of Cancer (Oxford, England : 1990)|July 12, 2002
Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, 2001)E Van Cutsem, M Dicato, J Wils, et al.European Journal of Cancer (Oxford, England : 1990)|March 19, 2018
Epstein-Barr virus and mismatch repair deficiency status differ between oesophageal and gastric cancer: A large multi-centre studyL C Hewitt, I Z Inam, Y Saito, et al.Bioorganic & Medicinal Chemistry Letters|August 7, 2013
Synthesis and structure-activity relationships of novel indazolyl glucocorticoid receptor partial agonistsJohn L Gilmore, James E Sheppeck, Jim Wang, et al.European Journal of Cancer (Oxford, England : 1990)|February 5, 2020
Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 studyE Van Cutsem, K Muro, D Cunningham, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 15, 2013
A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinomaA C Roy, S R Park, D Cunningham, et al.ESMO Open|December 20, 2023
Tislelizumab versus chemotherapy as second-line treatment for European and North American patients with advanced or metastatic esophageal squamous cell carcinoma: a subgroup analysis of the randomized phase III RATIONALE-302 studyJ Ajani, F El Hajbi, D Cunningham, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2000
European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphomaJ M Foran, A Z Rohatiner, D Cunningham, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 31, 2011
A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancerN Starling, F Vázquez-Mazón, D Cunningham, et al.Pageof 87